Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. (Q53058595)

10 May 2018

title

Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. (English)

1 reference

10 May 2018

1 reference

Ming-Shien Yen

1

1 reference

10 May 2018

Nae-Fong Twu

2

1 reference

10 May 2018

Chiung-Ru Lai

3

1 reference

10 May 2018

Huann-Cheng Horng

4

1 reference

10 May 2018

Kuan-Chong Chao

5

1 reference

10 May 2018

Chi-Mou Juang

6

1 reference

10 May 2018

language of work or name

English

0 references

publication date

3 July 2009

1 reference

10 May 2018

published in

Gynecologic Oncology

1 reference

10 May 2018

volume

114

1 reference

10 May 2018

issue

3

1 reference

10 May 2018

page(s)

415-419

1 reference

10 May 2018

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

1 reference

Intraperitoneal cisplatin with systemic thiosulfate protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

A prognostic model for ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Diagnostic plots to reveal functional form for covariates in multiplicative intensity models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Evaluating the yield of medical tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Influence of the gynecologic oncologist on the survival of ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Secondary cytoreductive surgery for recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

Tertiary cytoreduction in patients with recurrent ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.034

10.1016/J.YGYNO.2009.05.034

7 January 2021

Identifiers

DOI

1 reference

10 May 2018

release_cmmned2us5h35p5emivv3w5yui

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cmmned2us5h35p5emivv3w5yui

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

10 May 2018